Anti-saccharification nutritional composition and application thereof

Abstract

The invention discloses an anti-saccharification nutritional composition and application thereof, and belongs to the technical field of healthy food. The active ingredients of the anti-saccharification nutritional composition disclosed by the invention comprise HMOs and a food-grade antioxidant, breast milk oligosaccharide HMOs is taken as a main component and is combined with antioxidants such as vitamin C, vitamin E and N-acetylcysteine, so that formation of AGEs is reduced by reducing blood sugar fluctuation of a user, shortening maintenance time of a high blood sugar level and reducing inflammatory response and oxidative stress reaction, the purpose of resisting saccharification is achieved from the source, and the problems of skin yellowing and the like are remarkably improved.

Description

Technical Field

[0001] This invention relates to an anti-glycation nutritional composition and its application, belonging to the field of health food technology. Background Technology

[0002] Anti-glycation refers to the process of inhibiting or reducing the damage caused by glycation reactions to tissues and organs such as the skin, thereby delaying skin aging. Glycation is a non-enzymatic reaction between reducing sugars (such as glucose) and biological macromolecules such as proteins and lipids, forming advanced glycation end products (AGEs). These products damage collagen and elastin fibers in the skin, leading to loss of elasticity, wrinkles, and dullness. Reducing the accumulation of AGEs not only improves skin texture and delays aging, but more importantly, it can prevent and reduce the risk of various skin diseases, such as diabetic dermatitis.

[0003] Existing anti-glycation strategies include: reducing sugar intake, using skincare products containing antioxidants and anti-glycation ingredients, activating the body's anti-glycation defense mechanisms, drug intervention, and lifestyle modifications. For example, patent US 20210315804A1 relates to an injectable product containing hyaluronic acid and trehalose for preventing skin glycation. Experiments have shown that this product can significantly reduce the formation of CML (N(ε)-carboxymethyl lysine, an important advanced glycation end product) in the skin. Another example is the glycoside (white water lily extract) developed by a certain company, which is used in anti-glycation cosmetics. It can activate autophagy proteins and reduce the accumulation of glycation products in the skin.

[0004] However, the above-mentioned products all rely on injection, topical application, and other methods, which cannot reduce the formation of AGEs from the source. Furthermore, the cost of injection and other methods is relatively high, and they are relatively inconvenient to use. Summary of the Invention

[0005] To address the shortcomings of existing technologies, the present invention aims to provide an anti-glycation nutritional composition and its application. This composition, administered orally, reduces the formation of advanced glycation end products (AGEs) at their source, thereby alleviating skin yellowing. The composition primarily consists of human milk oligosaccharides (HMOs) combined with antioxidants such as vitamin C, vitamin E, and N-acetylcysteine. By reducing blood sugar fluctuations, shortening the duration of hyperglycemia, and decreasing inflammatory and oxidative stress responses, it reduces AGE formation, achieving anti-glycation at its source and improving issues such as dull, yellow skin.

[0006] To achieve the above objectives, the following technical solution is provided: This invention provides an anti-glycation nutritional composition whose active ingredients include HMOs and food-grade antioxidants.

[0007] In one embodiment, the HMOs include one or more of 2'-fucosylated lactose, 3-fucosylated lactose, lactose-N-neotetrasaccharide, 3'-sialylated lactose, and 6'-sialylated lactose; preferably, they include at least 2'-fucosylated lactose, lactose-N-neotetrasaccharide, and 3'-sialylated lactose.

[0008] In one embodiment, the food-grade antioxidant includes one or more antioxidants selected from vitamin C, vitamin E, quercetin, tea polyphenols, tannic acid, curcumin, N-acetylcysteine, glutathione, and alpha-lipoic acid (LA); preferably, vitamin C, vitamin E, and N-acetylcysteine ​​are used in combination.

[0009] In one embodiment, the anti-glycation nutritional composition comprises active ingredients including 2'-fucosylated lactose, lactose-N-neotetrasaccharide, and 3'-sialylated lactose, as well as food-grade antioxidants vitamin C, vitamin E, and N-acetylcysteine.

[0010] In one embodiment, the anti-glycation nutritional composition comprises 1-6 parts of 2'-fucosylated lactose, 1-2 parts of lactose-N-neotetrasaccharide, 1-2 parts of 3'-sialylated lactose, 0.1-0.4 parts of vitamin C, 0.05-0.1 parts of vitamin E, and 1-6 parts of N-acetylcysteine.

[0011] In one embodiment, the anti-glycation nutritional composition comprises 6 parts of 2'-fucosylated lactose, 2 parts of lactose-N-neotetrasaccharide, 1.5 parts of 3'-sialylated lactose, 0.4 parts of vitamin C, 0.1 parts of vitamin E, and 6 parts of N-acetylcysteine.

[0012] In one embodiment, the anti-glycation nutritional composition comprises 600 mg of 2'-fucosylated lactose, 200 mg of lactose-N-neotetrasaccharide, 150 mg of 3'-sialylated lactose, 40 mg of vitamin C, 10 mg of vitamin E, and 600 mg of N-acetylcysteine.

[0013] In one embodiment, the anti-glycation nutritional composition further includes edible adjuvants and excipients.

[0014] In one embodiment, the anti-glycation nutritional composition exerts its anti-glycation effect by reducing the accumulation of AGEs in serum and skin.

[0015] The present invention also provides the application of the above-described anti-glycation nutritional composition in the preparation of anti-glycation products.

[0016] In one embodiment, the anti-glycation product includes food, health products, or pharmaceuticals.

[0017] The present invention also provides an anti-glycation formulation, comprising the above-described anti-glycation nutritional composition and pharmaceutically acceptable or food-grade excipients.

[0018] In one embodiment, the anti-glycation agent is an oral liquid or tablet, powder, capsule, or granule.

[0019] Beneficial effects: The anti-glycation nutritional composition of the present invention uses HMOs as the main component of the nutritional composition, and is used in combination with antioxidants such as vitamin C, vitamin E, and N-acetylcysteine. By reducing blood sugar fluctuations, reducing the duration of hyperglycemia, and reducing inflammatory and oxidative stress responses, it reduces the formation of AGEs and achieves the purpose of anti-glycation from the source. (1) The anti-glycation nutritional composition of the present invention can effectively inhibit the generation of AGE in the skin. After 6 months of continuous intervention, the average value of AGE fluorescence on the skin surface decreased from 112.79 to 103.60, a decrease of 8%, which was 9% higher than the average fluorescence value of the control group, significantly reducing the accumulation of AGE on the skin surface of the subjects. (2) The anti-glycation nutritional composition of the present invention can effectively reduce the content of AGE in serum; under the combined intervention of HMOs and antioxidants, the content of AGE in serum is even slightly reduced, which is 5.5% lower than before the intervention, and significantly slows down the accumulation of AGE in serum; (3) The anti-glycation nutritional composition of the present invention can significantly improve skin yellowing. Under the combined treatment of HMOs and antioxidant complex, the yellowing of the skin decreased by 7.38%, which is a significant change compared with the 4.15% increase in the control group. Attached Figure Description

[0020] Figure 1 This is a graph showing the changes in AGE accumulation on the skin surface of the subjects before and after the intervention. Detailed Implementation

[0021] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. The specific embodiments described below further illustrate the present invention.

[0022] The source of the materials involved in this invention: Table 1. Sources of main materials and reagents

[0023] 2'-FL is 2'-fucosylated lactose; LNnT: lactose-N-neotetrasaccharide; 3'-SL is 3'-sialylated lactose. Example 1 Subjects: Volunteers will be recruited, aged 35 and above, regardless of gender, and limited to those working in offices. They will be divided into a "control group" and an "experimental group" according to the following criteria: The "control group" will maintain a balanced diet and good lifestyle and sleep habits. The "experimental group" will be assessed based on their daily dietary habits, which are characterized by high sugar (long-term, frequent consumption of sugary drinks), high fat, frequent consumption of fried and grilled foods, and a lack of regular exercise. The "control group" will consist of at least 10 participants, and each "experimental group" will have approximately 10 participants.

[0024] Table 2. Experimental Groups

[0025] One “antioxidant supplement” contains 40 mg of vitamin C, 10 mg of vitamin E, and 600 mg of N-acetylcysteine ​​(powder, to be taken with water, the same below); one “2'-FL” supplement contains 600 mg of 2'-FL; one “LNnT” supplement contains 200 mg of LNnT; one “3'-SL” supplement contains 150 mg of 3'-SL; one “HMOs” and “antioxidant” supplement contains 40 mg of vitamin C, 10 mg of vitamin E, 600 mg of N-acetylcysteine, 600 mg of 2'-FL, 200 mg of LNnT, and 150 mg of 3'-SL. Except for the differences in experimental components, the other excipients of the above preparations are consistent.

[0026] In addition to the test content, participants were required to refrain from consuming any additional nutritional supplements, using any skincare products with strong effects (including but not limited to whitening, anti-aging, and spot-fading) except for sun protection, and undergoing any medical aesthetic treatments during the testing period. The intervention lasted for 6 months, with data collected before and in the 6th month of the intervention.

[0027] 1. Serum sample collection: Serum samples were collected by professional medical staff using disposable vacuum blood collection tubes from the elbow vein, with 5 mL of whole blood collected. After being allowed to coagulate naturally at room temperature, the samples were centrifuged at 3000 rpm for 10 minutes. The supernatant serum was aliquoted into 1.5 mL sterile centrifuge tubes and labeled with a unique sample number. Finally, the samples were stored in an ultra-low temperature freezer at -80℃ for subsequent biochemical index testing.

[0028] 2. The ELISA kit is used to detect the AGE content in serum. Any qualified product that is commercially available in the field can be used for the AGE detection. Kits that meet the general industry standards are suitable for this method. Changes in the supplier or place of origin do not introduce systematic errors. Sample processing and testing shall be performed in accordance with the kit instructions.

[0029] Results Analysis 1. Changes in AGE accumulation in serum before and after intervention in the population Table 3. Trends in serum AGE accumulation before and after intervention in the population.

[0030] Note: 'a' indicates a significant difference between the pre- and post-intervention changes in experimental group 5 and the pre- and post-intervention changes in the control group (p≤0.05). The results in the table above show that, compared with the control group (20.35 ng / mL), the blank group showed significantly higher serum AGE levels before intervention (32.75 ng / mL). Furthermore, without intervention, the blank group showed a further increase in serum AGE levels after 6 months (40.39 ng / mL), representing a 23% increase compared to 6 months prior. In experimental groups 1-4, the rate of increase in serum AGE levels significantly decreased after 6 months of intervention, with increases of 19.2%, 13.5%, 15.2%, and 19% respectively compared to before intervention, but none reached a statistically significant effect. However, under the combined intervention of HMOs and antioxidants, the serum AGE levels even decreased slightly, by 5.5% compared to before intervention, significantly slowing the accumulation of AGE in the serum.

[0031] 2. The effects of AGE accumulation on the skin surface Skin autofluorescence (SAF) is a non-invasive, rapid detection technique. When specific wavelengths of ultraviolet light are irradiated onto the skin (usually the forearm), certain substances in the skin (primarily AGEs) absorb the light and emit another wavelength of light (fluorescence). The instrument quantifies the accumulation level of AGEs in the skin by detecting the intensity of this fluorescence. AGEs are naturally fluorescent substances, and their concentration in the skin is directly related to the detected fluorescence intensity. The higher the concentration, the stronger the fluorescence signal. It reflects not instantaneous blood sugar levels, but rather the accumulation of glycation stress in the body over the past few weeks to months.

[0032] Subjects were asked to sign an informed consent form to participate in the test. Skin autofluorescence (SAF) testing was performed on the subjects' skin before and after the test, with a testing period of 6 months. Skin samples were taken from the same locations as much as possible before and after the test. The test was conducted on the inner forearm skin of the subjects by trained and qualified operators using an approved SAF detection device. The device was operated according to the instruction manual, and calibration, maintenance, and results were recorded. Subsequent comparisons of data between groups were performed using the LSD method in one-way ANOVA, with a significance level set at p < 0.05.

[0033] The results are as follows Figure 1 As shown, the AGE fluorescence value in the control group (mean increase of 10.14) was significantly higher than that in the blank group (mean increase of 3.30) before and after the sampling time point. In experimental groups 1-4, the mean fluorescence values ​​increased by 9.69, 3.37, 6.56, and 3.84 before and after intervention, respectively. Although the increase in fluorescence value compared to the control group was lower, none of these increases were statistically significant. Consistent with changes in AGE accumulation in serum, in experimental group 5, which involved the combined action of HMOs and antioxidants, after 6 months of continuous intervention, the mean AGE fluorescence value on the skin surface decreased from 112.79 to 103.60, a decrease of 8%, compared to a 9% increase in the mean fluorescence value of the control group, significantly reducing AGE accumulation on the subject's skin surface.

[0034] 3. Effects on skin yellowness AGEs are yellowish-brown substances. When they accumulate in large quantities in the skin, they can make originally fair skin appear sallow and dull. Therefore, in order to investigate whether HMOs complex can affect skin condition by influencing the accumulation of AGEs on the skin surface, the yellowness of the skin of the above subjects was tested simultaneously.

[0035] Subjects were asked to sign an informed consent form to participate in the test. Before the test, the skin color b* value of each test area was measured using a chromameter (CM-700D, Konica Minolta, Japan) as the initial value. Six months after the intervention, the skin color b* value was measured again to assess the improvement in skin tone. According to the International Commission on Illumination (CIE), b* represents yellow-blue tint; the higher the value, the more yellow the skin tone. The test results are shown in Table 4. The test was conducted on the inner forearm skin of the subjects by trained and qualified operators. The instrument was operated according to the instructions, and calibration, maintenance, and results were recorded. Subsequent comparisons between groups were analyzed using the LSD method in one-way ANOVA, with a significance level set at p<0.05.

[0036] Table 4. Changes in skin yellowing in subjects before and after intervention

[0037] Note: b * Rate of change = (b after intervention) * -Pre-intervention b * ) / before intervention b * The average value represents the increase in skin yellowness after intervention, while a negative value represents the decrease in skin yellowness.

[0038] The results in the table show that the control group, without any intervention, experienced a significant increase in skin yellowing (0.29% compared to the blank group). Experimental groups 1-4 showed varying degrees of slower or even decreasing yellowing after intervention, but the changes were generally within 1%. Under the combined treatment of HMOs and antioxidant complex, skin yellowing decreased by 7.38%, a significant change compared to the 4.15% increase in the control group, indicating that simultaneous administration of HMOs complex and antioxidants can significantly improve skin yellowing.

[0039] The embodiments provided above are not intended to limit the scope of the invention, nor are the described steps intended to limit the order of execution. Any obvious modifications made to the invention by those skilled in the art based on existing common knowledge also fall within the scope of protection defined by the claims.

Claims

1. An anti-glycation nutritional composition, characterized in that, Its active ingredients include HMOs and food-grade antioxidants.

2. The anti-glycation nutritional composition according to claim 1, characterized in that, The HMOs include one or more of 2'-fucosylated lactose, 3-fucosylated lactose, lactose-N-neotetrasaccharide, 3'-sialylated lactose, and 6'-sialylated lactose.

3. The anti-glycation nutritional composition according to claim 1, characterized in that, The food-grade antioxidants include one or more antioxidants selected from vitamin C, vitamin E, quercetin, tea polyphenols, tannic acid, curcumin, N-acetylcysteine, glutathione, and alpha-lipoic acid.

4. The anti-glycation nutritional composition according to claim 1, characterized in that, Its active ingredients include 2'-fucosylated lactose, lactose-N-neotetrasaccharide and 3'-sialylated lactose, as well as food-grade antioxidants vitamin C, vitamin E and N-acetylcysteine.

5. The anti-glycation nutritional composition according to claim 1, characterized in that, Its active ingredients include 1-6 parts of 2'-fucosylated lactose, 1-2 parts of lactose-N-neotetrasaccharide, 1-2 parts of 3'-sialylated lactose, 0.1-0.4 parts of vitamin C, 0.05-0.1 parts of vitamin E, and 1-6 parts of N-acetylcysteine.

6. The anti-glycation nutritional composition according to claim 1, characterized in that, The anti-glycation nutritional composition also includes edible adjuvants and excipients.

7. The use of the anti-glycation nutritional composition according to any one of claims 1 to 6 in the preparation of anti-glycation products.

8. The application according to claim 7, characterized in that, The anti-glycation products include food, health products, or pharmaceuticals.

9. An anti-glycation agent, characterized in that, It includes the anti-glycation nutritional composition of any one of claims 1 to 6 and pharmaceutically acceptable or food-grade excipients.

10. The anti-glycation agent according to claim 9, characterized in that, The anti-glycation preparation is an oral liquid, tablet, powder, capsule, or granule.

Images